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Abstract
Background: Randomized controlled trials (RCTs) are the gold standard for trials assessing the effects of
therapeutic interventions; therefore it is important to understand how they are conducted. Our objectives were to
provide an overview of a representative sample of pediatric RCTs published in 2007 and assess the validity of their
results.
Methods: We searched Cochrane Central Register of Controlled Trials using a pediatric filter and randomly selected
300 RCTs published in 2007. We extracted data on trial characteristics; outcomes; methodological quality; reporting;
and registration and protocol characteristics. Trial registration and protocol availability were determined for each
study based on the publication, an Internet search and an author survey.
Results: Most studies (83%) were efficacy trials, 40% evaluated drugs, and 30% were placebo-controlled. Primary
outcomes were specified in 41%; 43% reported on adverse events. At least one statistically significant outcome was
reported in 77% of trials; 63% favored the treatment group. Trial registration was declared in 12% of publications
and 23% were found through an Internet search. Risk of bias (ROB) was high in 59% of trials, unclear in 33%, and
low in 8%. Registered trials were more likely to have low ROB than non-registered trials (16% vs. 5%; p = 0.008).
Effect sizes tended to be larger for trials at high vs. low ROB (0.28, 95% CI 0.21,0.35 vs. 0.16, 95% CI 0.07,0.25).
Among survey respondents (50% response rate), the most common reason for trial registration was a publication
requirement and for non-registration, a lack of familiarity with the process.
Conclusions: More than half of this random sample of pediatric RCTs published in 2007 was at high ROB and
three quarters of trials were not registered. There is an urgent need to improve the design, conduct, and reporting
of child health research.
Background
Randomized controlled trials (RCTs) are considered the
gold standard for research on therapeutic interventions
and provide the best evidence to inform and guide clini-
cal decision-making. Currently the number of pediatric
trials conducted and published lags behind that for
adults [1,2]. In addition, little is known about the risk of
bias, or validity, of pediatric RCTs.
Substantial evidence demonstrates that particular
study design features increase the likelihood of systema-
tic error, or bias, most often resulting in over-estimation
of treatment effects. Risk of bias (ROB) reflects the
degree to which the results of a trial should be believed
[3]. Building on previous research around methodologi-
cal quality of RCTs [4,5], the Cochrane Collaboration
recently introduced a tool designed to appraise ROB,
encompassing six domains related to the internal valid-
ity of a trial: sequence generation, allocation conceal-
ment, blinding, incomplete outcome data, selective
outcome reporting, and “other” potential threats to
validity [3].
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ciated with the design, conduct, and reporting of trials
include the International Committee of Medical Journal
Editors’ (ICMJE) statement on trial registration [6] and
reporting guidelines (http://www.equator-network.org)
such as the CONSORT Statement (Consolidated Stan-
dards of Reporting Trials) [7]. Trial registration is inte-
gral in addressing the bias associated with selective
outcome reporting by ensuring that investigators pro-
spectively provide details on their trial, allowing for
increased transparency and accountability [8]. The
CONSORT Statement was developed to ensure ade-
quate and transparent reporting upon completion of the
trial and comprises a checklist of items that should be
included in the publication of any RCT. Evidence sug-
gests that these strategies have positively influenced the
quality of published trials [9-11], but this has yet to be
assessed in pediatrics.
Given these recent initiatives to improve reporting and
assess ROB, we aimed to describe the state of pediatric
evidence using a representative sample of child health
RCTs published in 2007. Specific objectives were to
examine: 1) methodological quality, including ROB, and
its association with effect estimates; 2) the rate of trial
registration and author reasons for registration and non-
registration; and, 3) availability of trial protocols and
their consistency with publications.
Methods
Sample Selection
Using a pediatric filter, the Cochrane Central Register of
Controlled Trials (CENTRAL) was searched for trials
published in 2007 [12]. CENTRAL is comprised of
records of studies indexed in Medline and Embase, as
well as hand-search results, grey literature, and the trials
registers of Cochrane Review Groups [13]. As such, this
provided a thorough search for pediatric controlled
trials. Two thousand eight hundred thirty-two trials
were randomly ordered using a computer-generated list,
were screened consecutively for relevance, and the first
300 (approximately 10%) RCTs matching the criteria
below were selected. Trials were included if they were
published in English and included participants aged 0 to
18 years. If a trial studied both children and adults, it
was included if the upper age limit was ≤21 years [13].
Data Extraction
Data were extracted on: publication (e.g., type of journal,
impact factor) and trial characteristics; outcomes and
conclusions; methodological quality and reporting; and
trial registration and protocol characteristics related to
outcomes. Data extraction was completed by one
reviewer with an independent second review on a ran-
domly selected 10% sample. Discrepancies were resolved
through consensus and were negligible. Trial registration
and protocol availability were determined for each study
based on publication details, an Internet search, and
author follow-up.
Assessment of Methodological Quality and Reporting
Given the range of quality assessment methods available,
and the widespread use of many, methodological quality
and reporting were assessed using multiple tools: the
Jadad scale [4] and allocation concealment [5], as well
as the Cochrane ROB tool [3] and the 2001 CONSORT
Statement [14]. The Jadad scale is a five-point scale
based on the description of randomization, double-
blinding, and withdrawals or losses to follow-up; a score
of 5 indicates highest quality. Allocation concealment
was assessed as adequate, inadequate, or unclear. Nearly
all trials in our sample were efficacy trials; therefore we
focused on the original CONSORT Statement. The 2001
CONSORT checklist was the most recently published
version at the time of data extraction, and assesses
reporting with respect to 22 items. Each item was
assessed as fully, partially, or not met.
The ROB tool was applied based on guidelines estab-
lished by The Cochrane Collaboration [3], with some
modifications specific to our investigation (see Addi-
tional file 1). These consist of decision rules that have
been developed by our centre that have been used in
conjunction with the Cochrane guidelines to increase
consistency across reviewers. An overall assessment of
ROB was made as high, low, or unclear based on the
criteria from the Cochrane handbook: if any of the six
domains were judged to be at high risk of bias, the over-
all risk was considered high; if any were judged to be at
unclear risk of bias and none at high risk, the overall
risk was unclear; and if all six domains were judged to
be at low risk of bias, the overall risk was low. The tool
was pilot tested by all members of the study team. Trials
were assessed independently by two trained reviewers
who arrived at consensus for each of the six items.
Trial Registration and Protocol Availability
To determine whether or not trials were registered,
details were first sought in the publication. If a declara-
tion was not made, we searched through the Interna-
tional Clinical Trials Registry Platform (ICTRP) search
portal maintained by the World Health Organization
(WHO). If not found, the following registries were
searched in order: ClinicalStudyResults.org, Memorial
Sloan-Kettering Cancer Center, Current Controlled
Trials Meta-Register, and CenterWatch. While there
was some overlap in registries searched (i.e. ISRCTN.org
is included in both the ICTRP portal and the Current
Controlled Trials Meta-Register), each register contained
unique databases. If a trial was not found in any of these
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names of the first, last, and/or corresponding authors
and key words. When available, data from the registry
or from protocols found in our search were compared
to the publication.
A 28-question survey regarding trial registration and
protocol availability was sent to all corresponding
authors with current email contact information (n =
290; see Additional file 2). The initial invitation and sur-
vey link was followed by two reminders containing the
same information. Protocols were requested from
authors. Ethical approval was obtained from the Health
Research Ethics Board at the University of Alberta prior
to survey implementation.
Analysis
Data were analyzed descriptively, using means and stan-
dard deviations or medians and ranges for continuous
variables and proportions for categorical variables. Effect
sizes were computed for 236 trials with sufficient data
based on the primary outcome for that trial. The effect
size was a standardized mean difference when the pri-
mary outcome was continuous and a converted odds
ratio when dichotomous [15]. Effect sizes were pooled
using DerSimonian-Laird random effects for each of the
three ROB categories (high, low, unclear). To compare
ROB for certain covariates, a reference category was
chosen within each variable classification and odds
ratios comparing the number of high/unclear risk trials
to low risk trials were computed with 95% confidence
intervals.
Results
Description of Study Sample
Publication and trial characteristics of our sample of 300
trials are shown in Table 1. The majority of trials used
parallel designs (89.7%), were efficacy trials (82.7%), and
were published in specialty journals (78.6%). Evaluation
of pharmacological interventions was most common
(40.3%) and 30% of trials were placebo-controlled.
While all major geographic areas were represented, the
majority of authors were from Europe (40.3%) and
North America (29.0%). Each study was categorized
using the review groups of The Cochrane Collaboration:
neonatal (9.3%), oral health (7.7%), and developmental,
psychosocial, and learning problems (6.7%) were most
represented.
Methodological Quality
The median Jadad score was 2 (IQR 2-3). Allocation
concealment was adequate in 21.7% of trials, while
75.7% were unclear (Table 2). Only three trials (1.0%)
sufficiently addressed all 22 items of the CONSORT
Table 1 Publication and trial characteristics (N = 300)
Study Characteristic N (%)
Continent of corresponding author
Africa 11 (3.7)
Asia 58 (19.3)
Australia 16 (5.3)
Europe (excluding UK) 91 (30.3)
North America 87 (29.0)
South America 7 (2.3)
United Kingdom 30 (10.0)
Type of journal
General medical journal 19 (6.3)
Specialty medical journal 166 (55.3)
General pediatric journal 45 (15.0)
Specialty pediatric journal 70 (23.3)
Study design
RCT parallel 269 (89.7)
RCT crossover 19 (6.3)
RCT factorial 5 (1.7)
Other 7 (2.3)
Study type
Efficacy/Superiority 248 (82.7)
Equivalence 9 (3.0)
Non-inferiority 13 (4.3)
Not declared 2 (0.7)
None of the above 25 (8.3)
Unclear 3 (1.0)
Nature of intervention
Drug 121 (40.3)
Vaccine 16 (5.3)
Natural health product 26 (8.7)
Device 44 (14.7)
Other 93 (31.0)
Placebo-controlled 90 (30.0)
Number of centres
Multicentre 105 (35.0)
Single Centre 179 (59.7)
Unclear 16 (5.3)
Sample size
Mean (SD) 785.2 (5837.3)
Median (range), IQR 83 (6 - 71,799), 10 -
7079
Data Monitoring Committee established 14 (4.7)
Any adverse events reported 129 (43.0)
Funding source
Declared 194 (64.7)
Industry Sponsored 67/194 (34.5)
Primary outcome explicitly reported 123 (41.0)
At least one statistically significant outcome 230 (76.7)
Intervention favored
Treatment 189 (63.0)
Control 19 (6.3)
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partially meeting all requirements (IQR 15-19). The
remaining 289 trials (96.3%) failed to report at least one,
and up to 14 recommended items. Overall, the median
number of items that were adequately addressed was 15,
and five for those partially addressed. Descriptions of
the “method used to implement the randomization
sequence” (item 9) and “who generated the allocation
sequence and enrolled and assigned participants” (item
10) were the most under-reported, with 214 (71.3%) and
229 (76.3%) trials not meeting these criteria respectively.
Overall ROB was low for 23 trials (7.7%), unclear for
99 (33.0%), and high for 178 (59.3%) (Table 2). Much of
the uncertainty in rating studies was due to unclear
reporting. Selective outcome reporting was rated as low
ROB in nearly all trials. “Other” sources of bias included
inappropriate influence of the study sponsor (e.g. indus-
try funding without separation from the conduct of the
trial), imbalance in baseline characteristics, and design-
specific issues (e.g., factors related to cluster RCTs or
cross-over trials), and was the domain that was least
often addressed satisfactorily (Table 3). Trials at low
ROB had higher mean Jadad scores and were more
likely to report adequate means of allocation conceal-
ment than those at high ROB (Table 4).
Effect sizes tended to increase from studies at low
(0.16, 95% CI 0.07,0.25) to high ROB (0.28, 95% CI
0.21,0.35; p = 0.051; Figure 1).
Each of the ROB domains and the overall ratings were
examined in the context of the following variables: trial
registration, industry funding, multi-centre status, num-
ber of treatment arms, intervention type, primary out-
come category, and type of journal (see Additional file
3). Of these variables, trial registration had the most
influence on ROB. Compared to trials that were not
registered, those trials that were had a lower overall
ROB, as well as a lower ROB for each of the domains
except selective outcome reporting. Odds ratios for high
ROB ranged from 0.29 (95% CI 0.12,0.69) for overall
ROB to 0.47 (95% CI 0.27,0.81) for “other” sources of
bias. Trials that were sponsored by industry were more
likely to have adequate blinding than non-industry
funded trials (OR 0.41 (95% CI 0.22,0.76)), but were also
more likely to be associated with “other” sources of bias
(OR 4.72 (95% CI 2.46,9.07)). ROB for selective outcome
reporting increased with number of arms in the trial
(p = 0.007), but was unchanged for the other domains.
When compared to pharmacological interventions, trials
investigating devices had a higher ROB associated with
blinding (OR 3.37 (95% CI 1.62,7.02)) and incomplete
data (OR 2.56 (95% CI 1.26,5.21)). High ROB due to
blinding was also found in studies with outcomes related
to techniques/training (e.g., longevity of dental restora-
tions) when compared to physiological outcomes (OR
5.28 (95% CI 1.09,25.61)). Multi-centre status and type
of journal had no impact on ROB.
Table 2 Assessments of methodological quality (N = 300)
Methodological Quality Indicator N (%)
Jadad
Mean (SD) 2.6 (1.2)
Median (range) 2 (0 - 5)
Allocation Concealment
Adequate 65 (21.7)
Unclear 227 (75.7)
Inadequate 8 (2.7)
Risk of Bias
Low 23 (7.7)
Unclear 99 (33.0)
High 178 (59.3)
CONSORT Statement
Items fully addressed (median, range) 15 (4-22)
Items partially addressed (median, range) 5 (0-14)
Items not addressed (median, range) 2 (0-7)
Trial registered
Declared in publication 37 (12.3)
Registration found online 69 (23.0)
Study protocol available from corresponding author 2/290 (0.7)
Table 3 Risk of bias assessments by domain (N = 300)
Domain Risk of bias assessments - N (%)
High Unclear Low
Sequence generation 8 (2.7%) 143 (47.7%) 149 (49.7%)
Allocation concealment 8 (2.7%) 217 (72.3%) 75 (25.0%)
Blinding 41 (13.7%) 108 (36.0%) 151 (50.3%)
Incomplete data 60 (20.0%) 53 (17.7%) 187 (62.3%)
Selective reporting 48 (16.0%) 6 (2.0%) 246 (82.0%)
“Other” sources of bias 85 (28.3%) 109 (36.3%) 106 (35.3%)
Table 1 Publication and trial characteristics (N = 300)
(Continued)
Neither 92 (30.7)
Common primary diagnostic categories
Acute Respiratory Infections 17 (5.7)
Airways 14 (4.7)
Anaesthesia 18 (6.0)
Developmental, Psychosocial, and Learning
Problems
20 (6.7)
Ear, Nose, and Throat Disorders 10 (3.3)
Infectious Disease 19 (6.3)
Metabolic and Endocrine Disorders 15 (5.0)
Neonatal 28 (9.3)
Oral Health 23 (7.7)
Public Health 16 (5.3)
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trials (12.3%) and 69 records of registration (23.0%)
were found online. Registered trials were more likely to
be published in journals with a higher impact factor
(median 4.017 vs. 1.883; p < 0.0001). Approximately one
third of trials were registered in studies with corre-
sponding authors from Africa (36.4%), North and South
America (34.5% and 28.6%, respectively), and the UK
(30.0%), but proportions were lower for the rest of Eur-
ope (18.7%), Asia (10.3%), and Australia (6.3%). Regis-
tered trials more often specified their funding source
(89.9% vs. 57.1%; p < 0.0001), and less often reported
statistically significant findings, although this compari-
son was not statistically significant (68.1% vs. 79.2%; p =
0.07). Measures of methodological quality were superior
in registered trials (Table 4).
Author Follow-Up Survey
145 authors (50.0%) responded to the survey, therefore
the ability to generalize findings is limited. Of respon-
dents, 61 (42.4%) reported registration with a public
trial registry, potentially corresponding closely to the 69
found in our search. The majority of these were regis-
tered with ClinicalTrials.gov (67.5%) or Current Con-
trolled Trials (17.5%). 51.2% were registered prior to
and 37.2% after patient recruitment. The most common
reason for registering a trial was a journal requirement
for publication (72.7%), followed by a belief in full public
disclosure (68.2%). For non-registration, the most com-
mon reasons were lack of familiarity with the process
(59.1%) and trial initiation prior to registration endorse-
ment by the ICMJE (51.5%) (Table 5).
Nearly all respondents (92.2%) had prepared a study
protocol prior to trial initiation; 2.0% reported a minor
difference between the protocol and study conduct. 9.7%
of authors reported that some outcomes measured in
the trial were not reported in the publication. Space
Table 4 Trial characteristics and quality assessment stratified by trial registration and overall risk of bias (N = 300)
Trial Characteristics N Trial Registered Risk of Bias
300 Yes (N = 69;23%) No
(N = 231;77%)
Low
(N = 23;8%)
Unclear
(N = 99;33%)
High
(N = 178;59%)
Impact factor (median, range) 294 4.017 (0.581-52.589) 1.883 (0.080-15.484) 2.948 (0.475-10.169) 1.850 (0.329-52.589) 2.342 (0.080-28.638)
Continent of corresponding author
Africa 11 4 (5.8) 7 (3.0) 1 (4.4) 4 (4.0) 6 (3.4)
Asia 58 6 (8.7) 52 (22.5) 6 (26.1) 27 (27.3) 25 (14.0)
Australia 16 1 (1.5) 15 (6.5) 2 (8.7) 7 (7.1) 7 (3.9)
Europe (excluding UK) 91 17 (24.6) 74 (32.0) 6 (26.1) 27 (27.3) 58 (32.6)
North America 87 30 (43.5) 57 (24.7) 5 (21.7) 19 (19.2) 63 (35.4)
South America 7 2 (2.9) 5 (2.2) - 2 (2.0) 5 (2.8)
United Kingdom 30 9 (13.0) 21 (9.1) 3 (13.0) 13 (13.1) 14 (7.9)
Funding source specified 194 62 (89.9) 132 (57.1) 23 (100.0) 49 (49.5) 122 (68.5)
Industry supported 67 24/62 (38.7) 43/132 (32.6) 7/23 (30.4) 8/49 (16.3) 52/122 (42.6)
Primary outcome explicitly stated 123 41 (59.4) 82 (35.5) 14 (60.9) 34 (34.3) 75 (42.1)
Statistically significant outcome 230 47 (68.1) 183 (79.2) 15 (65.2) 83 (83.8) 132 (74.2)
Data Monitoring Committee 14 9 (13.0) 5 (2.2) 1 (4.4) 5 (5.1) 8 (4.5)
Jadad score (mean; median, range) 300 2.99 (3; 0-5) 2.44 (2; 0-5) 3.96 (4; 3-5) 2.24 (2; 1-5) 2.56 (2; 0-5)
Allocation Concealment
Adequate 65 24 (34.8) 41 (17.8) 20 (87.0) 15 (15.2) 30 (16.9)
Unclear 227 45 (65.2) 182 (78.8) 3 (13.0) 84 (84.9) 140 (78.7)
Inadequate 8 - 8 (3.5) - - 8 (4.5)
Trial registered 69 NA NA 11 (47.8) 10 (10.1) 48 (27.0)
Risk of Bias
Low 23 11 (15.9) 12 (5.2) NA NA NA
Unclear 99 10 (14.5) 89 (38.5)
High 178 48 (69.6) 130 (56.3)
Figure 1 Effect size estimates according to overall risk of bias.
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imposed space limitation 41.7%; authors’ concern about
space 25.0%), followed by non-statistically significant
findings (41.7%). While 56.4% of respondents indicated
that they were willing to share their protocol, only two
were received. In both cases, the details in the publica-
tion were consistent with the protocol.
Discussion
Our sample of recently-published pediatric trials
demonstrates that there is considerable room for
improvement in their design, conduct, and reporting.
Methodological quality was modest, with the vast major-
ity of trials at high or unclear ROB. Further, the trials
did not adhere to widely accepted reporting standards
or requirements for trial registration.
Our sample was intended to be representative of all
RCTs published in 2007; therefore we placed no restric-
tions on journal, clinical area, or type of intervention.
Trials in our sample were largely published in specialty
journals, and examined a variety of interventions among
a diverse range of conditions.
Methodological quality was assessed using three well-
recognized tools and the results overall were not favor-
able, suggesting methodological weaknesses and high
risk of bias. Incomplete reporting was prevalent; while
statements declaring implementation of certain design
features (e.g., randomization and “double-blinding”)
were common, detailed methods were often not speci-
fied. Further, allocation concealment was rarely
addressed at all. Despite the differing emphasis of the
tools used (i.e., conduct for ROB and quality of report-
ing for Jadad and CONSORT), the results were consis-
tent in that overall, the trials did not meet the criteria of
any of the methods of assessment. However, there is evi-
dence to suggest that the Jadad scale and ROB measure
different constructs and that the assessment of ROB
may be more appropriate [16].
Selective outcome reporting is of great concern. It is
one of the driving forces for the promotion of trial
registration and has important implications for safety
[17-20]. To assess this domain, we compared the out-
comes specified in the protocol or in the trial register to
those reported in the publication; however the lack of
registered trials and the extremely low response to
requests for protocols made this difficult. As a result,
our findings likely underestimate the risk associated
with this particular issue, as we were unable to assess
potential biases introduced through discrepancies
between the original trial design and actual conduct.
Evidence suggests that industry-funded trials are more
likely to report favorable results [21-23], therefore we
included a criterion within the “other” sources of bias
domain that related to inappropriate influence of the
Table 5 Author responses to follow-up survey (N = 145)
Survey Question N (%)
Was your trial registered with a public trial registry?
Yes 61 (42.4)
No 83 (57.6)
No response 1
What were your reasons for registering your trial (select all that apply)?
I believe that trials should be registered as a means of full public disclosure 30 (68.2)
I endorse the statement regarding public trial registration made by the ICJME 23 (52.3)
Trial registration is necessary for publication in some peer-reviewed journals 32 (72.7)
Trial registration was required by the funding agency 5 (11.4)
Trial registration was required by the Research Ethics Board 9 (20.5)
Trial registration is institutional policy 2 (4.5)
Other 3 (6.8)
No response 101
What were your reasons for not registering your trial (select all that apply)?
Lack of time 3 (4.5)
Lack of resources 5 (7.6)
I was not familiar with the process for trial registration 39 (59.1)
Cost associated with registration 4 (6.1)
I don’t see a benefit to trial registration 1 (1.5)
Trial was initiated prior to registration endorsement by the ICMJE 34 (51.5)
No formal requirement 4 (6.1)
Other 7 (10.6)
No response 79
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declared and a statement was made outlining the role of
the sponsor, we considered the trial to be low ROB for
that measure; however this information was often miss-
ing. While funding source was not the only considera-
tion in assessing “other” sources of bias, it was relevant
to every trial, and was therefore important in the deter-
mination of our overall results showing high or unclear
ROB for this domain among two thirds of trials.
We found a noteworthy trend toward increasing effect
estimates with increasing ROB which is consistent with
previous research [16]. Trials at high ROB had a larger
mean effect size than trials at low ROB, indicating the
potential for a high proportion of trials to be reporting
exaggerated results. These results are exploratory and
should be interpreted with caution given the heteroge-
neity in outcomes compared and the small number of
studies. Further work and methods that better account
for confounding due to intervention and diagnostic con-
dition are required before firm conclusions can be made.
D e s p i t ew i d es u p p o r t[ 2 4 ] ,u p t a k eb yj o u r n a l so ft h e
CONSORT Statement has been variable. In a survey of
165 high impact journals in 2007, 38% mentioned the
CONSORT Statement in the instructions to authors and
14% required (rather than recommended) it to be com-
pleted for a trial to be accepted [25]. This variability is
echoed in our sample, as very few trials met all of the
requirements of the checklist. Of the 11 trials that at
least partially met all requirements, nine journals were
represented. Of these, two journals stated in their
instructions to authors that a completed CONSORT
checklist was required, three recommended following
the CONSORT guidelines, and the remainder did not
mention the CONSORT Statement. Our observation
that journal endorsement of the CONSORT Statement
has little bearing on whether all of the recommended
elements are reported highlights the practical issue of
how to ensure adherence to the guidelines, and ulti-
mately their impact on reporting.
Very few trials in our sample were registered in a pub-
lic registry, and only about half of those that were regis-
tered declared this in the publication. Prospective trial
registration has been heavily endorsed, and the volume
of trials registered appears to be increasing [26-28].
However, trial registration is far from universal, and is
perhaps more problematic in pediatric trials. Pandolfini
and Bonati [29] found that the proportion of pediatric
trials among all registered trials in online registers was
disproportionate to those in the published literature.
Pediatric trials are more likely to be published in speci-
alty journals which may be less likely to require trial
registration than general medical journals. Another con-
cern is that the requirement for trial registration may
not be enforced. Our author survey suggests that one of
the major barriers to trial registration among respon-
dents is a lack of familiarity with the process; therefore,
efforts are required to raise awareness. These efforts
should target researchers at the study design stage,
rather than at the point of publication. However, reluc-
tance on the part of academic researchers to publicly
disclose the information required by trial registers may
p o s eac h a l l e n g e[ 3 0 ] ,a ni ssue that was reinforced in
this study by the apparent futility of contacting authors
for access to protocol data. Potential future directions in
this area may include the requirement of publicly avail-
able protocols at the time of trial registration or with
funding applications.
Based on our findings, there is clearly room for
improvement in pediatric trials. This is the mission of
StaR Child Health (Standards for Research in Child
Health), an international group that was recently formed
involving varied stakeholders to develop and promote
guidance to ensure the validity and relevance of pedia-
tric trials [31]. With the involvement of trialists, clini-
cians, regulators, editors, and representatives of the
pharmaceutical industry, this initiative is invested in
meeting the needs of the research and clinical commu-
nities [32]. Through the development of standards for
research in priority areas for pediatric research (e.g.
appropriate outcome selection, data and safety monitor-
ing committees, sample size, ROB), StaR Child Health
aims to be an important contributor to a methodologi-
cally strong evidence base for pediatric care [33].
Limitations
We included approximately 10% of pediatric RCTs pub-
lished in 2007, potentially limiting representativeness.
Only trials published in English were included, possibly
contributing to the high proportion of studies from
North America and the UK. While we extracted the
country of the corresponding author, this is not a per-
fect proxy for the population studied and in some cases,
an author from a high income country reported on a
trial conducted in a low or middle income area.
The true ROB was often difficult to interpret in our
sample due to poor reporting. Additionally, the issue of
selective outcome reporting posed a challenge as proto-
cols or trial registers were unavailable for the majority
of studies. In most cases, the publication was judged
according to its internal consistency. Hence, the high
proportion of trials that were given a rating of low ROB
for this domain likely underestimates the true ROB.
The pooled analysis presented to examine trends in
effect sizes and ROB is preliminary work. Given the het-
erogeneity in diseases, interventions, and outcomes
included in the sample, we used standardized measures
of effect size to be able to investigate general patterns
across studies, but these results are exploratory.
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to response bias. The item responses indicate that
authors who had registered their trials were more likely
to participate in the survey, potentially limiting applic-
ability. Assuming that respondents were more aware of
issues related to trial registration and methodological
initiatives in general, the answers provided (for example
reasons for non-registration) may not encompass some
of the deeper issues faced by other researchers and may
have implications for attempts to overcome these bar-
riers in the future.
Conclusions
This study shows that the majority of pediatric trials
published in 2007 were at high risk of bias, correspond-
ing with a trend toward increased effect sizes. In spite of
a movement towards improving methodological quality
and requirements for trial registration, the majority of
trials have not met these recommendations. These
results should be of great concern for child health provi-
ders, researchers, methodologists, and funders, and
should motivate all to work towards improving the
design, conduct, and reporting of child health research.
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Additional file 1: Guidelines and Decision Rules for Risk of Bias
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